Search Within

Igor Odintsov

  1. "Lukas Delasos"
Formats
  1. Journal Article (5)
  2. Meeting Abstract (1)
Groups
  1. Department of Pathology and Laboratory Medicine (6)
  2. GSK Faculty (6)
  3. Human Oncology and Pathogenesis Program (6)
  4. Sloan Kettering Institute Postdocs (6)
  5. Tow Center for Developmental Oncology (TCDO) (6)
  6. Department of Medicine (2)

More Groups

People
  1. Elisa De Stanchina (6)
  2. Lukas Delasos (6)
  3. Marc Ladanyi (6)
  4. Marissa Mattar (6)
  5. Romel Somwar (6)
  6. Inna Khodos (5)

More People

Years
  1. 2023 (1)
  2. 2022 (1)
  3. 2021 (3)
  4. 2020 (1)
Publications
  1. Disease Models & Mechanisms (2)
  2. Clinical Cancer Research (1)
  3. European Journal of Cancer (1)
  4. Journal of Thoracic Oncology (1)
  5. Nature Cancer (1)
Publishers
  1. Company of Biologists (2)
  2. Elsevier Inc. (2)
  3. American Association for Cancer Research (1)
  4. Nature Research (1)

Results (6)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations
    Journal Article

    Miyazaki, I.; Odintsov, I.; Ishida, K.; Lui, A. J. W.; Kato, M.; Suzuki, T.; Zhang, T.; Wakayama, K.; Kurth, R. I.; Cheng, R.; more...
    Nature Cancer (2023)

    Fulltext@MSK | Save
  • Novel patient-derived models of desmoplastic small round cell tumor confirm a targetable dependency on ERBB signaling
    Journal Article

    Smith, R. S.; Odintsov, I.; Liu, Z.; Lui, A. J. W.; Hayashi, T.; Vojnic, M.; Suehara, Y.; Delasos, L.; Mattar, M. S.; Hmeljak, J.; more...
    Disease Models & Mechanisms (2022)

    Fulltext@MSK | Save
  • Novel preclinical patient-derived lung cancer models reveal inhibition of HER3 and MTOR signaling as therapeutic strategies for NRG1 fusion-positive cancers
    Journal Article

    Odintsov, I.; Mattar, M. S.; Lui, A. J. W.; Offin, M.; Kurzatkowski, C.; Delasos, L.; Khodos, I.; Asher, M.; Daly, R. M.; Rekhtman, N.; more...
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save
  • The anti-HER3 mAb seribantumab effectively inhibits growth of patient-derived and isogenic cell line and xenograft models with oncogenic NRG1 fusions
    Journal Article

    Odintsov, I.; Lui, A. J. W.; Sisso, W. J.; Gladstone, E.; Liu, Z.; Delasos, L.; Kurth, R. I.; Sisso, E. M.; Vojnic, M.; Khodos, I.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • RET inhibition in novel patient-derived models of RET fusion-positive lung adenocarcinoma reveals a role for MYC upregulation
    Journal Article

    Hayashi, T.; Odintsov, I.; Smith, R. S.; Ishizawa, K.; Liu, A. J. W.; Delasos, L.; Kurzatkowski, C.; Tai, H.; Gladstone, E.; Vojnic, M.; more...
    Disease Models & Mechanisms (2021)

    Fulltext@MSK | Save
  • The anti-HER3 monoclonal antibody seribantumab effectively inhibits growth of patient-derived and isogenic cell line and xenograft models with NRG1 rearrangements
    Meeting Abstract

    Odintsov, I.; Gladstone, E.; Sisso, W. J.; Delasos, L.; Lui, A. J. W.; Sisso, E. M.; Vojnic, M.; Khodos, I.; Mattar, M. S.; de Stanchina, E.; more...
    European Journal of Cancer (2020)

    Fulltext@MSK | Save